

Press Release

Excellence in Biopharmaceutical Innovation in Germany. Award for Rodos BioTarget GmbH from Acquisition International Magazine

Hannover, Germany/ Staffordshire, United Kingdom, September 23, 2014.

The Acquisition International Magazine announced the winners of its prestigious 2014 Business Excellence Awards. Voted for by a worldwide network of professionals, advisers, clients, peers and business insiders, the Acquisition International Business Excellence Awards celebrate the individuals and firms whose commitment to excellence sees them exceeding clients' expectations on a daily basis while setting the bar for others in their industry. The awards, open to businesses from any sector or region, are now in their second year and are handed out solely on merit. They are given to only the most deserving businesses, departments and individuals who have consistently demonstrated outstanding innovation, performance and commitment to their business or clients over the past 12 months and who have received independent nominations from their clients or industry peers.

Against this background, Rodos BioTarget GmbH was awarded for its "Excellence in Biopharmaceutical Innovation – Germany". As Dr. Marcus Furch, Rodos BioTarget's CEO commented: "The award means for us an exceptional recognition of our work and our achievements by advancing the concept of targeted drug delivery accepted by the pharmaceutical industry".

About Rodos BioTarget

According to the company's mission statement, *'To become the industry leader in targeted drug delivery by providing TargoSphere® nanocarriers for enabling significantly enhanced prophylactic and therapeutic approaches against devastating diseases'*, Rodos BioTarget GmbH consequently develops its TargoSphere® technology platform. By allowing to address different cell types by employing diverse targeting anchor, TargoSpheres® are of great interest for the pharmaceutical industry: Suitable active agents can now be delivered directly to their intracellular site of action and thus help solve problems in the control of infections as well as malignant and autoimmune diseases. In addition, TargoSpheres® allow to re-define already established active ingredients for making them more effective and/or less burdened with side-effects. In non-partnered programs, Rodos BioTarget develops antibacterial and antiviral TargoBiotics® and TargoVir® applications for combatting intracellular infections. For additional information, please see www.biotargeting.eu

Contact: Dr. M. Furch (CEO), + 49 176 3921 3096 and Dr. R. Gieseler-von der Crone (CSO), +49 176 6292 9350 / Rodos BioTarget GmbH / info@biotargeting.eu